Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC has formed a strategic partnership with BBI Solutions to manufacture monoclonal antibodies for a lung cancer detection test. The collaboration aims to supply the first commercial batch of antibodies, supporting up to 5000 assays, and is a critical step toward the commercialization and regulatory strategy of the company. This advancement is set to aid in early detection of lung cancer, with potential expansion into other cancer detection tests.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
